Patients Active in Research and Dialogues for an Improved Generation of Medicines (PARADIGM) is a 30-month IMI-funded project (from March 2018 to August 2020) with public and private partners representing patient organisations, pharmaceutical industry, not-for-profit organisations, regulators and HTA bodies.

The main objective is to provide a framework that will enable a meaningful, impactful, ethical and sustainable patient engagement.

As EUPATI is focusing on patient education to enable patient engagement, the collaboration with IMI-PARADIGM is very important when it comes to sharing case studies, inputting in working groups and organising the Patient Engagement Open Forum.

The collaboration between EUPATI and IMI-PARADIGM:

Patient Engagement Open Forum

This event is co-organised by EUPATI, IMI-PARADIGM and Patient Focused Medicines Development (PFMD) and it aims to provide a holistic perspective on patient engagement, the landscape and actors, and foster collaboration and co-creation while breaking down fragmentation and silos that are often present in patient engagement work.

Patient Engagement Toolbox

PARADIGM will deliver a set of tools to enable stakeholders to do patient engagement in a meaningful and systematic way. The tools will be searchable via the EUPATI Toolbox.

EUPATI Guidance on Patient Involvement in Medicines Research & Development

Under the IMI-PARADIGM project, the EUPATI guidance on patient involvement for pharmaceutical industry-led medicines R&D has been revised and 2 addendums added to the guidance. It can be found here.

Patient Engagement Open Forum - highlights (2019)